FGFR3 and cyclic hematopoiesis: Based on methylation profiling with methylation sequencing (methyl-seq), we conclude that hypomethylation at FGFR3 CpG sites is the leading driver of FGFR3 overexpression, which triggers downstream activation of the PI3K-AKT pathway that ultimately leads to CN development and progression.